# The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease

> **NCT01161914** · PHASE3 · WITHDRAWN · sponsor: **ISU Abxis Co., Ltd.**

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** Cerezyme®
- **DRUG:** ISU302

## Key facts

- **NCT ID:** NCT01161914
- **Lead sponsor:** ISU Abxis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-01
- **Primary completion:** 2011-08
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01161914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01161914, "The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01161914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*